Research advances on current situation and management strategies of re-fractures after osteoporotic fractures
10.3760/cma.j.cn121113-20220530-00307
- VernacularTitle:骨质疏松性骨折后再骨折现状及管理策略的研究进展
- Author:
Junjie LI
1
;
Peng JIA
;
Youjia XU
Author Information
1. 苏州大学附属第二医院骨科，苏州 215004
- From:
Chinese Journal of Orthopaedics
2022;42(22):1514-1522
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of osteoporosis and its resulting osteoporotic fractures is increasing year by year. More and more scholars pay attention to the fact that the 2 years after osteoporotic fractures is a high-risk period for re-fractures and the key window period for secondary fracture prevention. Osteoporotic fractures are important risk factors for re-fractures, and many other factors, such as the time interval after fracture and fracture site, affect the occurrence of re-fractures. Therefore, traditional fracture risk assessment tools are not suitable for the re-fracture risk assessment, while preliminary reports of emerging re-fracture risk assessment tools have been available. In recent years, with the worldwide promotion of fracture liaison service (FLS), the comprehensive management strategies have effectively improved the diagnosis rate, treatment rate and drug compliance of patients with osteoporotic fractures, while reducing the risk of re-fractures. However, there are a variety of FLS projects with different models around the world, clinicians in some countries and regions have insufficient understanding and attention to the absence of management after osteoporotic fractures, and the risk of re-fractures is still imminent. Therefore, this article systematically elaborated the latest status of re-fractures after osteoporotic fractures, risk factors affecting re-fractures and new re-fracture risk assessment tools. The prevention and management strategies of re-fractures are summarized from three aspects: the standardized anti-osteoporosis drug therapy, the multidisciplinary FLS, as well as the early and personalized rehabilitation therapy, in order to provide references for clinical management of osteoporotic fractures in China.
